Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 185 of the 186 references it cites were found in a registry or an index.

Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration

Fuller-Carter, Paula I., Basiri, Hamed, Harvey, Alan R., Carvalho, Livia S. · 2020 · BioDrugs

Abstract

Inherited retinal diseases (IRDs) comprise a clinically and genetically heterogeneous group of disorders that can ultimately result in photoreceptor dysfunction/death and vision loss. With over 270 genes known to be involved in IRDs, translation of treatment strategies into clinical applications has been historically difficult. However, in recent years there have been significant advances in basic research findings as well as translational studies, culminating in an increasing number of clinical trials with the ultimate goal of reducing vision loss and associated morbidities. The recent approval of Luxturna® (voretigene neparvovec-rzyl) for Leber congenital amaurosis type 2 (LCA2) prompts a review of the current clinical trials for IRDs, with a particular focus on the importance of adeno-associated virus (AAV)-based gene therapies. The present article reviews the current state of AAV use in gene therapy clinical trials for IRDs, with a brief background on AAV and the reasons behind its dominance in ocular gene therapy. It will also discuss pre-clinical progress in AAV-based therapies aimed at treating other ocular conditions that can have hereditable links, and what alternative technologies are progressing in the same therapeutic space.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40259-020-00453-8

Cites

185 of 185 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 186 references

Cited by

See all 41

Metadata

Authors
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S.
Affiliations
  • Lions Eye Institute (AU)
  • The University of Western Australia (AU)
Venue
BioDrugs
Published
2020-11-02
Volume
34
Issue
6
Pages
763-781
ISSN
  • 1172-7039 (ISSN-L)
  • 1173-8804
  • 1179-190X
OpenAlex
W3094654915
Cited by
41
References
186
Citations by year
2026: 2 · 2025: 4 · 2024: 10 · 2023: 9 · 2022: 6 · 2021: 10
FWCI
0.60
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • BioDrugs (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
adeno-associated virus, inherited retinal degeneration, ocular gene therapy, clinical trials, Luxturna, voretigene neparvovec, vision loss, photoreceptor dysfunction
MeSH terms
Dependovirus, Clinical Trials as Topic, Genetic Vectors, Humans, Retinal Degeneration, Genetic Therapy, Leber Congenital Amaurosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration. https://app.cochat.ai/papers/10.1007/s40259-020-00453-8
The paper
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020). Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration. BioDrugs. https://doi.org/10.1007/s40259-020-00453-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.